Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.31 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL169896 | 0.80 | CA1 (0.38) | HDAC1HDAC6CA12CA1CA2 | |
| SCHEMBL4060447 | 0.79 | KDM1A (0.31) | KDM1AKDM1BHDAC1HDAC6CA12 | |
| SCHEMBL716485 | 0.79 | HDAC1 (0.35) | KDM1AKDM1BHDAC1HDAC6 | |
| SCHEMBL25073989 | 0.78 | CA1 (0.39) | KDM1AKDM1BHDAC1HDAC6CA1 | |
| SCHEMBL19880474 | 0.78 | CYP3A4 (0.39) | HDAC1HDAC6CA1CA2 | |
| SCHEMBL22118356 | 0.78 | CA1 (0.39) | KDM1AKDM1BCA12CA1CA2 | |
| SCHEMBL31243056 | 0.78 | SOS1 (0.30) | — | |
| SCHEMBL9876027 | 0.78 | POLB (0.30) | — | |
| SCHEMBL9675381 | 0.75 | POLB (0.37) | — | |
| SCHEMBL31243034 | 0.75 | SOS1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466803-B2 | BCKDK inhibitors and/or degraders | PFIZER INC. (US) | 2025-11-11 | — | — | US | disclosed |
| CN-118451066-A | 3-Phenyl-1-benzothiophene-2-carboxylic acid derivatives as inhibitors of branched alpha ketoacid dehydrogenase kinase for the treatment of diabetes, kidney disease, NASH and heart failure | 辉瑞大药厂 | 2024-08-06 | — | — | CN | disclosed |
| WO-2023100061-A1 | 3-PHENYL-1-BENZOTHIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS BRANCHED-CHAIN ALPHA KETO ACID DEHYDROGENASE KINASE INHIBITORS FOR THE TREATMENT OF DIABETES, KIDNEY DISEASES, NASH AND HEART FAILURE | PFIZER INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023100061-A1 | 3-PHENYL-1-BENZOTHIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS BRANCHED-CHAIN ALPHA KETO ACID DEHYDROGENASE KINASE INHIBITORS FOR THE TREATMENT OF DIABETES, KIDNEY DISEASES, NASH AND HEART FAILURE | PFIZER INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20230167080-A1 | BCKDK INHIBITORS AND/OR DEGRADERS | PFIZER INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167080-A1 | BCKDK INHIBITORS AND/OR DEGRADERS | PFIZER INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167080-A1 | BCKDK INHIBITORS AND/OR DEGRADERS | PFIZER INC. (US) | 2023-06-01 | — | — | US | disclosed |
| CN-110128231-A | A kind of preparation method of diaryl acetylene compound | 南京邮电大学 | 2019-08-16 | — | — | CN | disclosed |
| US-8097594-B2 | Macrolides and ketolides having antimicrobial activity | WOCKHARDT LTD. (IN) | 2012-01-17 | — | — | US | disclosed |
| US-20090247478-A1 | Novel macrolides and ketolides having antimicrobial activity | SINDKHEDKAR MILIND DATTATRAYA | 2009-10-01 | — | — | US | disclosed |
| US-20060178515-A1 | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-08-10 | — | — | US | disclosed |
| EP-1611104-A1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004085403-A1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-10-07 | — | — | WO | disclosed |
| EP-0237955-B1 | QUINOLONECARBOXYLIC ACID DERIVATIVES AND THEIR PREPARATION | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1992-07-15 | — | — | EP | disclosed |
| US-4894458-A | BACTERICIDES | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1990-01-16 | — | — | US | disclosed |
| EP-0237955-A2 | Quinolonecarboxylic acid derivatives and their preparation | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1987-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466803-B2 | BCKDK inhibitors and/or degraders | BCKDK, KHK, PDK4 | KDM1A 607/4885KDM1B 924/4885HDAC1 760/4885 |
| US-20230167080-A1 | BCKDK INHIBITORS AND/OR DEGRADERS | BCKDK, KHK, PDK4 | KDM1A 607/4885KDM1B 924/4885HDAC1 760/4885 |
| US-20090247478-A1 | Novel macrolides and ketolides having antimicrobial activity | CYP51A1, CASP12, LSS | KDM1A 1445/4885KDM1B 1317/4885HDAC1 73/4885 |
| US-20060178515-A1 | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists | HCRTR2, HCRTR1, OXTR | KDM1A 1928/4885KDM1B 1771/4885HDAC1 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.